Department of Internal Medicine 1, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
Department of Internal Medicine 2, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
PLoS One. 2022 May 24;17(5):e0268638. doi: 10.1371/journal.pone.0268638. eCollection 2022.
The efficacy of antibiotic prophylaxis to prevent rebleeding or infection after variceal bleeding in patients with liver cirrhosis colonized with multidrug-resistant organisms (MDROs) is unknown.
In this retrospective study, patients with liver cirrhosis and endoscopically confirmed variceal bleeding who were treated at a tertiary care center in Germany and were screened for MDROs at the time of bleeding were eligible for inclusion. Efficacy of antibiotic prophylaxis was evaluated in patients stratified according to microbiological susceptibility testing.
From 97 patients, the majority had decompensated liver cirrhosis (median MELD Score 17) and ACLF was present in half of the patients (47.4%). One third of patients were colonized with MDRO at baseline. De-novo infection until day 10 or the combination of de-novo infection or rebleeding were comparable among both groups (p = 0.696 and p = 0.928, log-rank-test). Risk of de-novo infection or rebleeding was not significantly increased in patients who received antibiotic prophylaxis that did not cover the MDRO found upon baseline screening. Acute-on-chronic liver failure at baseline was the strongest and only independent risk factor that was associated with both outcomes (OR 5.52, 95%-CI 1.48-20.61, p = 0.011 and OR 11.5, 95%-CI 2.70-48.62, p<0.001). Neither MDRO colonization at baseline nor covering all detected MDRO with antibiotic prophylaxis (i.e. "adequate" prophylaxis) impacted transplant-free survival. Again, the presence of ACLF was the strongest independent risk factor associated with mortality (OR 9.85, 95%-CI 3.58-27.12, p<0.0001).
In this study, MDRO colonization did not increase the risk of rebleeding, infections nor death, even if antibiotic prophylaxis administered did not cover all MDRO detected at MDRO screening. Patients with ACLF had an increased risk of bleeding, infections and death.
对于肝硬化合并多重耐药菌(MDROs)定植的患者,预防静脉曲张出血后再出血或感染的抗生素预防效果尚不清楚。
在这项回顾性研究中,我们纳入了在德国一家三级护理中心治疗的经内镜证实有静脉曲张出血且在出血时筛查 MDROs 的肝硬化患者。根据微生物敏感性检测对患者进行分层,评估抗生素预防的效果。
在 97 例患者中,大多数为失代偿性肝硬化(中位 MELD 评分 17),半数患者存在 ACLF(47.4%)。三分之一的患者基线时存在 MDRO 定植。在两组中,直到第 10 天的新发感染或新发感染或再出血的组合无显著差异(p = 0.696 和 p = 0.928,log-rank 检验)。在基线筛查发现的 MDRO 未被抗生素预防覆盖的情况下,接受抗生素预防并未显著增加新发感染或再出血的风险。基线时的急性慢性肝衰竭是与两种结局均相关的最强和唯一独立危险因素(OR 5.52,95%CI 1.48-20.61,p = 0.011 和 OR 11.5,95%CI 2.70-48.62,p<0.001)。基线时的 MDRO 定植或用抗生素预防覆盖所有检测到的 MDRO(即“适当”预防)均不影响无移植生存。同样,ACLF 的存在是与死亡率相关的最强独立危险因素(OR 9.85,95%CI 3.58-27.12,p<0.0001)。
在这项研究中,MDRO 定植并未增加再出血、感染或死亡的风险,即使给予的抗生素预防未覆盖 MDRO 筛查中检测到的所有 MDRO。ACLF 患者有更高的出血、感染和死亡风险。